Chronic Steroid Use in Asthma Linked to rising Health Costs, Comorbidities
Table of Contents
A new study reveals the significant economic and health burdens associated with long-term oral corticosteroid (OCS) use among adults with asthma, highlighting a critical need to re-evaluate treatment strategies. Asthma affects over 25 million Americans, with associated healthcare costs already reaching nearly $82 billion annually – a figure projected to increase if uncontrolled asthma remains prevalent, according to the research published in the Journal of Allergy and Clinical Immunology: Global.
The Escalating Costs of Asthma Treatment
The study underscores a growing concern: while oral corticosteroids remain a common treatment for asthma due to their anti-inflammatory properties, their chronic use carries significant risks. Researchers analyzed data from a large claims database encompassing 826,065 patients, revealing a clear correlation between prolonged OCS exposure and increased healthcare utilization and costs.
“The current use and overuse of chronic OCS, and underuse of controller therapies, remains a challenge to the current US medical systems with potential consequences on long-term health, productivity, life expectancy, and health care costs,” the study authors concluded.
Defining Chronic OCS Use & Patient Groups
researchers categorized patients into three groups based on their OCS usage patterns between January 2015 and December 2019:
- Continuous users: Those taking ≥10 mg/day for at least 90 days.
- Cumulative users: Those taking ≥500 mg over 12 months.
- Burst users: those experiencing ≥2 “bursts” of OCS treatment within 12 months.
A total of 86,708 patients met the inclusion criteria, with significant overlap between the groups.The data revealed that continuous users, even before initiating OCS treatment, were generally older and had a higher burden of existing health conditions.
Increased Risks & Comorbidities
Following chronic OCS use, continuous users experienced a markedly higher rate of comorbidities – the presence of multiple diseases simultaneously. Specifically, these patients showed increased incidence of diabetes, obesity, cardiovascular events, psychiatric disorders, osteoporosis, and digestive disorders.
The financial implications are equally concerning. Total medical costs for patients following chronic OCS use ranged from $3,997 to $9,482 per patient per year, while pharmacy costs ranged from $1,167 to $2,034 annually.
According to the Mayo Clinic, it’s crucial to carefully weigh the risks and benefits of OCS use, given commonly reported adverse events like fluid buildup, high blood pressure, weight gain, and psychological effects.
A Growing Public health concern
With nearly 1 in 13 Americans diagnosed with asthma – representing an estimated 44.2 million individuals – the implications of these findings extend far beyond individual patient care. While asthma prevalence has stabilized since 2010, it substantially increased between 2001 and 2010. The increasing rates of obesity,diabetes,and metabolic disorders in the US amplify the impact of OCS overuse on population health.
“With rapidly increasing rates of obesity, diabetes mellitus, and metabolic disorder in the US, the increasing impact of OCS overuse on population health…and its potential to cause comorbid disease, is poorly appreciated, but should be further explored,” the study authors stated.
The research emphasizes the urgent need for a shift towards alternative asthma management strategies and a more judicious approach to OCS prescribing, ultimately aiming to improve long-term health outcomes and reduce the escalating economic burden of this widespread respiratory condition.
